Tardive Dyskinesia Research Review
  • CME
  • CE

Two expert faculty members discuss key articles in tardive dyskinesia research and the clinical implications, strengths, limitations, and salient conclusions.
Sanjay Gupta, MD
Joseph P. McEvoy, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Pharmacists: 0.75 contact hours (0.075 CEUs)
Physician Assistants: maximum of 0.75 hours of AAPA Category I CME credits
Released: August 31, 2021 Expiration: August 30, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate the clinical and economic outcomes associated with TD diagnosis and treatments
  • Review TD assessment and screening techniques and respective caveats
  • Define and clarify TD phenomenology and symptoms

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Sanjay Gupta, MD

Clinical Professor
Department of Psychiatry
SUNY at Buffalo Jacobs School of Medicine
Chief Medical Officer
BryLin Behavioral Health System
Buffalo, New York

Sanjay Gupta, MD has disclosed that he has received speaker fees from AbbVie, Alkermes, Intracellular, Janssen, Neurocrine, Otsuka, and Sunovion; and consulting fees from Intracellular Therapies.
Joseph P. McEvoy, MD

Professor
Psychiatry and Health Behavior
Psychiatrist
Augusta University
Augusta, Georgia

Joseph P. McEvoy, MD has disclosed that he has received funds for research support from Alkermes, Auspex, Biogen, Boehringer-Ingelheim, Neurocrine, and Takeda and consulting fees from Intracellular and Sunovion.

Staff

Aditi Nadkarni, PhD
Aditi Nadkarni, PhD, has no relevant conflicts of interest to report.
Lisa Phipps, PharmD, PhD
Lisa Phipps, PharmD, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, NP, has no relevant conflicts of interest to report.
Mark Christiansen, PhD, PA-C
Mark Christiansen, PA, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists engaged in the care of patients with psychiatric illness.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of tardive dyskinesia.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-168-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until August 30, 2022. PAs should only claim commensurate with the extent of their participation.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 31, 2021, through August 30, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Slides from a presentation that educates clinicians on Huntington disease and the management of chorea

Victor W. Sung, MD Released: September 17, 2021

Slides from a presentation on strategies to improve treatment-resistant depression from a global perspective.

Siegfried Kasper, MD Released: September 3, 2021

Slides from a presentation that educates clinicians on strategies to improve depression treatment and future directions of treatment.

Pim Cuijpers, PhD Released: September 3, 2021

Slides from a presentation that educates clinicians on evaluation of mental health-related apps, patient privacy, and informed decision-making.

John Torous, MD Released: September 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue